Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Bancroft

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Hepatology Communications|September 30, 2022
Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United StatesMindie H Nguyen, Lewis R Roberts, Nicole M Engel-Nitz, et al.
Advances in Therapy|March 23, 2024
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims AnalysisBenjamin Chastek, Adam Carrera, Christina Landis, et al.
Neurourology and Urodynamics|May 9, 2024
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims studyBenjamin Chastek, Adam Carrera, Christina Landis, et al.
BMC Gastroenterology|September 17, 2024
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARYNoa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factorsPhaedra Johnson, Tim Bancroft, Richard Barron, et al.
Journal of Medical Economics|March 10, 2025
Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysisSandra Sze-Jung Wu, Michelle Vu, Omar Motawakel, et al.
Science (New York, N.Y.)|December 8, 2009
Paternal dominance of trans-eQTL influences gene expression patterns in maize hybridsRuth A Swanson-Wagner, Rhonda DeCook, Yi Jia, et al.
Journal of Comparative Effectiveness Research|October 29, 2014
Field testing the ENSEMBLE Minimum Dataset: performance of an instrument to address heterogeneity of treatment effectsSusan K Brenneman, Wei Shen, Lee Brekke, et al.
The Oncologist|February 28, 2019
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's LymphomaCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
The Oncologist|February 24, 2019
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal CancerCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Hepatology Communications|September 30, 2022
Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United StatesMindie H Nguyen, Lewis R Roberts, Nicole M Engel-Nitz, et al.
Advances in Therapy|March 23, 2024
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims AnalysisBenjamin Chastek, Adam Carrera, Christina Landis, et al.
Neurourology and Urodynamics|May 9, 2024
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims studyBenjamin Chastek, Adam Carrera, Christina Landis, et al.
BMC Gastroenterology|September 17, 2024
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARYNoa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factorsPhaedra Johnson, Tim Bancroft, Richard Barron, et al.
Journal of Medical Economics|March 10, 2025
Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysisSandra Sze-Jung Wu, Michelle Vu, Omar Motawakel, et al.
Science (New York, N.Y.)|December 8, 2009
Paternal dominance of trans-eQTL influences gene expression patterns in maize hybridsRuth A Swanson-Wagner, Rhonda DeCook, Yi Jia, et al.
Journal of Comparative Effectiveness Research|October 29, 2014
Field testing the ENSEMBLE Minimum Dataset: performance of an instrument to address heterogeneity of treatment effectsSusan K Brenneman, Wei Shen, Lee Brekke, et al.
The Oncologist|February 28, 2019
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's LymphomaCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
The Oncologist|February 24, 2019
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal CancerCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
Pageof 5